Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind positive-control trial of lyophilized human rabies vaccine (human diploid cell) with different post-exposure immunization schedules
CTR20254433Phase 3Active
- Sponsor
- Changchun Baimu Biotechnology
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rabies virus inactivated antigen, B in rabies, sponsored by Changchun Baimu Biotechnology. Started Mar 2026; status: active.
02
Drugs
rabies virus inactivated antigen, B
03
Conditions
rabies
Beyond the preview
Go deeper on CTR20254433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254433.